Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Protein Kinase C Theta Type - Drugs In Development, 2022'; Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-θ) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation, and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-costimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediates inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway.

The report 'Protein Kinase C Theta Type - Drugs In Development, 2022' outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology and Metabolic Disorders which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Breast Cancer, Ewing Sarcoma, Heart Transplant Rejection, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Obesity, Prostate Cancer and Type 2 Diabetes.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
• The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
• The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
Companies Mentioned

Astellas Pharma Inc
Bristol-Myers Squibb Co
EpiAxis Therapeutics Pty Ltd
Evommune Inc
HotSpot Therapeutics Inc